Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer

被引：0
|
作者：
Samuel Murray
Vasilios Karavasilis
Mattheos Bobos
Evangelia Razis
Savvas Papadopoulos
Christos Christodoulou
Paris Kosmidis
George Fountzilas
机构：
[1] BioMarker Solutions Ltd,Department of Molecular Oncology
[2] GeneKOR,Department of Medical Oncology
[3] “Papageorgiou” Hospital,Department of Pathology
[4] Aristotle University of Thessaloniki School of Medicine,First Department of Medical Oncology
[5] Aristotle University of Thessaloniki School of Medicine,Department of Pathology
[6] “Hygeia” Hospital,Second Department of Medical Oncology
[7] “Hygeia” Hospital,Second Department of Medical Oncology
[8] “Metropolitan” Hospital,undefined
[9] “Hygeia” Hospital,undefined
来源：
Journal of Experimental & Clinical Cancer Research | / 31卷
关键词：
Predictive; Somatic mutation; EGFR; Gefitinib; Erlotinib; Response;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] Predicting clinical benefit in non-small-cell lung cancer patients treated with epidermal growth factor tyrosine kinase inhibitors
    Amler, L. C.
    Goddard, A. D.
    Hillan, K. J.
    MOLECULAR APPROACHES TO CONTROLLING CANCER, 2005, 70 : 483 - 488
  • [32] INCIDENCE OF HEPATITIS B REACTIVATION DURING EGFR TYROSINE KINASE INHIBITORS TREATMENT IN NON-SMALL-CELL LUNG CANCER PATIENTS
    Yao, Zong-Han
    Liao, Wei-Yu
    Ho, Chao-Chi
    Chen, Kuan-Yu
    Shih, Jin-Yuan
    Chen, Jin-Shing
    Lin, Zhong-Zhe
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    Yu, Chong-Jen
    RESPIROLOGY, 2018, 23 : 291 - 291
  • [33] Mechanisms of Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients with Advanced Non-Small-Cell Lung Cancer: Clinical and Molecular Considerations
    Pallis, A.
    Briasoulis, E.
    Linardou, H.
    Papadimitriou, C.
    Bafaloukos, D.
    Kosmidis, P.
    Murray, S.
    CURRENT MEDICINAL CHEMISTRY, 2011, 18 (11) : 1613 - 1628
  • [34] Update of epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer
    Chen, Yuh-Min
    JOURNAL OF THE CHINESE MEDICAL ASSOCIATION, 2013, 76 (05) : 249 - 257
  • [35] Tyrosine Kinase Inhibitors for Acute Respiratory Failure Because of Non-small-Cell Lung Cancer Involvement in the ICU
    Tandjaoui-Lambiotte, Yacine
    Akrour, Yanis
    Gibelin, Aude
    Gonzalez, Frederic
    Stoclin, Annabelle
    Moreau, Anne-Sophie
    Jaubert, Paul
    Oppenheimer, Anne
    Duchemann, Boris
    Gaudry, Stephane
    CHEST, 2022, 161 (01) : 284 - 287
  • [36] Predictive Biomarkers to Tyrosine Kinase Inhibitors for the Epidermal Growth Factor Receptor in Non-Small-Cell Lung Cancer
    De Luca, A.
    Normanno, N.
    CURRENT DRUG TARGETS, 2010, 11 (07) : 851 - 864
  • [37] Locally advanced/metastatic non-small-cell lung cancer in Lebanon: focus on ALK tyrosine kinase inhibitors
    Tfayli, Arafat
    Ghanem, Hady
    Nasr, Fadi
    Kourie, Hampig Raphael
    El Hachem, Georges
    Debs, Jamil
    Masri, Sarah
    Assi, Hazem, I
    Campelo, Rosario Garcia
    Kattan, Joseph
    FUTURE ONCOLOGY, 2025, 21 (01) : 127 - 137
  • [38] EGF receptor tyrosine kinase inhibitors in the treatment of brain metastases from non-small-cell lung cancer
    Bartolotti, Marco
    Franceschi, Enrico
    Brandes, Alba Ariela
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1429 - 1435
  • [39] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Stinchcombe, Thomas E.
    CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2016, 17 (04)
  • [40] The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer
    Thomas E. Stinchcombe
    Current Treatment Options in Oncology, 2016, 17
12345